Regional Account Manager - NYC/Philadelphia/Baltimore
AbbottSalary not specified
- Full Time
- Junior (1 to 2 years)
Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, Neurology, Medical Devices & EquipmentIndustries
Requirements
Candidates must possess a Bachelor’s degree, with preferred degrees in life sciences, business, or healthcare, and a minimum of 5 years of pharmaceutical, biotech, or healthcare sales experience. A minimum of 3 years of rare disease or highly specialized sales experience, including selling high-cost products through a specialty pharmacy, is required. Proven track record of exceeding sales targets and successfully managing a territory, along with experience selling in specialized clinics, hospitals, and academic centers, is also necessary.
Responsibilities
The Regional Account Manager will be directly responsible for representing PTC’s products to medical professionals specializing in neurological diseases and/or Friedreich's Ataxia (FA) within their assigned region, handling all operational aspects of pharmaceutical sales and services, including generating sales, communicating product benefits, building relationships, educating healthcare staff, and identifying new opportunities. They will achieve assigned sales targets in a compliant manner, implement marketing strategies, collaborate with internal and external teams, develop business partnerships with physicians and healthcare staff, identify key treatment centers, cultivate relationships with patient advocacy groups, employ a consultative sales approach, address product access issues, and perform additional tasks as needed.
Skills
Pharmaceutical sales
Neurology
Friedreich's Ataxia
Relationship building
Healthcare education
Regulatory compliance
Cross-functional collaboration
Marketing strategy
Patient engagement
Solution-oriented sales
Axsome Therapeutics Inc
Develops therapies for CNS disorders
About Axsome Therapeutics Inc
Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.
Key Metrics
New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees